News
VOGX
20.25
+1.66%
0.33
Weekly Report: what happened at VOGX last week (1019-1023)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 10/22 12:05
Why QuantumScape Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/22 09:08
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 10/21 21:05
Weekly Report: what happened at VOGX last week (1012-1016)?
Weekly Report · 10/19 10:34
Vogenx initiates Phase 2b EMERGE study of mizagliflozin
TipRanks · 10/15 20:40
Vogenx Initiates EMERGE, Phase 2b Clinical Trial Evaluating Mizagliflozin For Treatment Of Post-Bariatric Hypoglycemia
Benzinga · 10/15 20:37
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Barchart · 10/15 15:35
Weekly Report: what happened at VOGX last week (1005-1009)?
Weekly Report · 10/12 10:41
Vogenx Names Rich Gorman Chief Commercial Officer
TipRanks · 10/09 17:57
Vogenx appoints Gorman as Chief Commercial Officer
TipRanks · 10/09 12:05
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Barchart · 10/09 07:00
Weekly Report: what happened at VOGX last week (0928-1002)?
Weekly Report · 10/05 10:40
Weekly Report: what happened at VOGX last week (0921-0925)?
Weekly Report · 09/28 10:34
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/24 21:05
Vogenx appoints Ken Toombs to board, audit chair
TipRanks · 09/22 20:39
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 09/22 17:06
Vogenx appoints Ken Toombs to board of directors
TipRanks · 09/22 13:20
Biotech Stocks At 52-Week Highs - HSCS +7%, FRNM +5%, VOGX, HTFL, HALO
NASDAQ · 09/21 13:35
Weekly Report: what happened at VOGX last week (0914-0918)?
Weekly Report · 09/21 10:34
More
Webull provides a variety of real-time VOGX stock news. You can receive the latest news about Vogenx through multiple platforms. This information may help you make smarter investment decisions.
About VOGX
Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The Company's primary objective is to advance its lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome, or GDCS. Mizagliflozin is a selective inhibitor of SGLT1, a glucose transporter present in the gastrointestinal tract responsible for transporting dietary glucose into the bloodstream. Its VGX-2857 is a novel small molecule-based product candidate that is orally available. VGX-2857 is a combination of two novel small molecules that have demonstrated the potential to aid in weight loss in one fixed dosage form.